|
|
| |
| |
Your access to vital information on gynecologic cancers is now easier, with comprehensive coverage of this topic at your fingertips. ASCO has gathered and synthesized data on gynecologic cancers from a multitude of key sources, including the Journal of Clinical Oncology and other ASCO publications, the Virtual Meeting, and more. Experience the ease of finding in-depth information on gynecologic cancers topics, and visit often to remain current with timely updates.
|
|
| |
|
JCO Highlighted Gynecologic Cancers Articles
|
Last Updated: October 20, 2009
|
 |
|
Quality of Life After Pelvic Radiotherapy or Vaginal Brachytherapy for Endometrial Cancer: First Results of the Randomized PORTEC-2 Trial
(JCO, July 2009)
|
|
|
Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
(JCO, March 2009)
|
|
|
Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
(JCO, March 2009)
|
|
|
Phase II Evaluation of Nanoparticle Albumin?Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
(JCO, March 2009)
|
|
|
Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
(JCO, March 2009)
|
|
|
|
|
Medline Latest Gynecologic Cancers Articles
|
Last Updated: November 1, 2009
|
|
|
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
(J Clin Oncol, 2009 Aug)
|
|
|
Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
(J Clin Oncol, 2009 Aug)
|
|
|
In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells.
(Cancer Res, 2009 Sep)
|
|
|
Resveratrol suppresses growth of human ovarian cancer cells in culture and in a murine xenograft model: eukaryotic elongation factor 1A2 as a potential target.
(Cancer Res, 2009 Sep)
|
|
|
Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma.
(Clin Cancer Res, 2009 Apr)
|
|
|
|
|
Virtual Meeting
|
|
|
View gynecologic cancers track presentations from the 2008 ASCO Annual Meeting. In addition, search gynecologic cancers presentations from previous meetings.
|
|
|
|
Abstracts
|
|
|
Search the 2008 gynecologic cancer abstracts as well as abstracts back through the 2000 Annual Meeting
|
|
|
|
Educational Book
|
|
|
Find gynecologic cancer manuscripts grouped into areas of interest, or search the 2002-2009 Educational Books archive.
|
|
|
|
Cancer.Net
|
|
|
Find information and resources to support your patients living with gynecologic cancers
|
|
|
|
|
|
|
|
 |
|
2010 ASCO Annual Meeting
McCormick Place – Chicago, IL
June 4 - 8, 2010
|
|
|
